source
- CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’sBiogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…BioSpace · 4h ago↗ source
- FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancersThe U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…